Table 1.
Sequential serological, biochemical and virological findings in an HIV-infected individual with markers of prior HBV infection at baseline.
| Characteristics | Date (month/year) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10/85 | 11/87 | 10/001 | 01/011 | 05/011 | 11/061 | 01/071 | 01/081 | 05/09 | 12/09 | 02/10 | 02/10 | 03/10 | 04/10 | 05/10 | 07/10 | |
| HBsAg (IU/ml) | NEG | NEG | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -- | 168 | 183 | 132 | 66 | 0.1 | 0.0 |
| Anti-HBs (mIU/ml) | POS | POS | <10 | <10 | <10 | <10 | <10 | <10 | <10 | -- | 140 | 124 | 87 | 61 | 50 | 24 |
| Anti-HBc | POS | POS | POS | POS | POS | POS | POS | POS | POS | -- | POS | POS | POS | -- | POS | POS |
| Anti-HBc IgM | NEG | NEG | -- | -- | -- | -- | -- | -- | -- | -- | POS | POS | POS | NEG | -- | -- |
| HBeAg | NEG | NEG | -- | -- | -- | -- | -- | -- | -- | -- | POS | NEG | NEG | -- | -- | -- |
| Anti-HBe | NEG | NEG | -- | -- | -- | -- | -- | -- | -- | -- | POS | POS | POS | -- | -- | -- |
| HBV DNA (IU/ml) | -- | -- | R (3) | R (7) | 19 | NR | NR | NR | NR | -- | 88,185 | 5,622 | 998 | 26 | R (4) | NR |
| AST (U/l) | 17 | 19 | 31 | 58 | 30 | 20 | 21 | 23 | 28 | 80 | 2,702 | 143 | 41 | -- | 23 | 19 |
| ALT (U/l) | 14 | 16 | 35 | 68 | 37 | 14 | 14 | 14 | 19 | 111 | 2,577 | 306 | 42 | -- | 17 | 21 |
| CD4+ T (cells/µl) | 891 | 883 | 48 | 29 | 48 | 478 | 580 | 516 | 513 | 304 | 291 | -- | -- | -- | 423 | 333 |
| HIV-RNA2(copies/ml) | -- | -- | 147,018 | 222,107 | 146,707 | <50 | <50 | NR | NR | 80,558 | -- | -- | 734 | -- | NR | NR |
| Antiretroviral therapy | Naive | Naive | No3 | No3 | No3 | Yes4 | Yes4 | Yes4 | Yes4 | No5 | No5 | Yes6 | Yes6 | Yes6 | Yes6 | Yes6 |
IU/ml = International Units/milliliter; mIU/ml = International milliunits/ml; U/l = Units/liter; NEG = negative; POS = positive; R = reactive below cut-off (<10IU/ml); HBV DNA calculated by the regression curve in brackets; NR = not reactive; -- = not determined.
1molecular and serological markers of HBV infection were retrospectively determined in February 2010 using automated Abbott HBV RealTime and Abbott ARCHITECT HBV assays, respectively
2HIV viremia was evaluated by Versant HIV RNA assay 3.0 (bDNA; Siemens Healthcare Diagnostics, Deerfield, IL) up to 01/2007 and by Abbott HIV RealTime since 01/2008.
3Previous antiretroviral therapy (Didanosine, Lamivudine, Nevirapine) was started on 04/2000 and interrupted on 08/2000; Lamivudine daily dose was 300 mg.
4Therapy was resumed in 02/2002 with different drug combinations including Lamivudine (300 mg daily) with or without Tenofovir (245 mg daily).
5Therapy (Lamivudine and Atazanavir) was interrupted on 10/2009.
6Therapy was resumed in 02/2010, including co-formulated Emtricitabine/Tenofovir (200/245 mg daily) plus boosted Darunavir.